TOBY Inc. Completes MedTech Accelerator Participation
TOBY, Inc., a pioneering biotechnology firm dedicated to transforming early cancer screening, has successfully concluded its involvement in the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator program. This prestigious initiative selected only ten innovative companies from a competitive pool of applicants for its 2025 cohort.
Innovative Technology for Early Cancer Detection
TOBY is at the forefront of developing an advanced noninvasive urine spectroscopy and Artificial Intelligence (AI) platform, aiming to revolutionize early cancer detection. This cutting-edge technology evaluates distinctive molecular signatures present in urine samples, thereby facilitating early, accessible, and economical screening options.
Support from the MedTech Accelerator
The Mayo Clinic and Arizona State University MedTech Accelerator provides vital support to early-stage medical technology ventures. Participants benefit significantly from access to a wealth of clinical, academic, and commercial resources, which contributes to their growth and innovation.
Mentorship and Strategic Guidance
Throughout the program, participating companies receive invaluable mentorship and strategic direction, ensuring they remain connected within the MedTech Accelerator’s extensive network.
Addressing the Critical Need for Screening
Matthew Laskowski, CEO of TOBY, emphasized the urgent demand for accessible and affordable cancer screening methods. He expressed that involvement in the MedTech Accelerator has been crucial in refining their technology and development approach.
Rising Cancer Incidence
According to projections from the International Agency for Research on Cancer (IARC), the global incidence of cancer is expected to escalate dramatically between 2022 and 2045. The National Cancer Institute estimates that over 2 million individuals in the United States are likely to receive a cancer diagnosis by 2025.
Aiming for Effective Treatment
Dragan Sebišanovi?, Chief Science Officer at TOBY, articulated a vital goal: to support earlier cancer detection when treatments are most beneficial and to alleviate burdens on both patients and the healthcare system. Leveraging machine learning, their technology actively identifies molecular patterns linked to early-stage cancers.
About TOBY, Inc.
Inspired by the tenacity of Sherlock Holmes's Bloodhound, TOBY, Inc. is a BioTech startup revolutionizing early cancer detection through the integration of spectroscopy and Artificial Intelligence. They have developed a single urine test capable of detecting 10 different types of cancer, which account for more than 60% of all new cases worldwide. This breakthrough test utilizes the precision of spectroscopy, changes in biomarkers (Volatile Organic Compounds), and advanced computational algorithms to facilitate early, easy, and affordable cancer screening.
Frequently Asked Questions
What is TOBY, Inc. known for?
TOBY, Inc. specializes in developing innovative technology for early cancer detection using urine spectroscopy and AI.
What is the MedTech Accelerator program?
The MedTech Accelerator program supports early-stage medical technology companies with resources, mentorship, and strategic guidance.
Why is early cancer detection important?
Early cancer detection increases treatment effectiveness and can significantly reduce the impact on patients and healthcare systems.
How does TOBY's technology work?
TOBY's technology analyzes unique molecular signatures in urine to detect various types of cancer noninvasively.
What is the significance of the partnership with Mayo Clinic and ASU?
This partnership provides TOBY with critical support and resources to advance its innovative technology and market strategy.
